Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Fine Closes ‘Pay-For-Delay’ Investigation That Began In 2011
Nov 26 2020
•
By
Dean Rudge
Teva committed to stay out of the modafinil markets "because of the substantial value transferred to it by Cephalon," the EC found. • Source: Shutterstock
More from Regulation
More from Policy & Regulation